Wolfram Klapper
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wolfram Klapper has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
A Sotnikova
Department of Haematopathology and Lymph Node Registry Kiel, Schleswig‐Holstein University Hospitals, Campus Kiel, Niemannsweg 11, 24105 Kiel, Germany
1 shared publicationAnna Sotnikova
Department of Pathology, Haematopathology and Lymph Node Registry, Schleswig‐Holstein University Hospitals, Kiel, Germany
1 shared publication- Eva Hoster
Institute for Medical Information Processing, Biometry, and Epidemiology (IBE), LMU Medizin, Ludwig-Maximilians-Universität München, Munich, Germany
1 shared publication Gaixiang Xu
Department of Pathology, Haematopathology and Lymph Node Registry, Schleswig‐Holstein University Hospitals, Kiel, Germany
1 shared publication- Hans-Juergen Heidebrecht
Institute for Immunology, University Hospital Schleswig-Holstein Campus Kiel, Arnold-Heller-Str. 3, Bldg 17, Kiel, 24105, Germany
1 shared publication J Greeve
Department of Internal Medicine, Inselspital‐University Hospital Bern, 3010 Bern, Switzerland
1 shared publication
Latest Publications
- 14 March 2011
- Published by Wiley in Histopathology
- Vol. 58 (4) , 586-592
Follicular dendritic cells in follicular lymphoma and types of non‐Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome
Jin M K, Hoster E, Dreyling M, Unterhalt M, Hiddemann W & Klapper W (2011) Histopathology 58, 586–592 Follicular dendritic cells in follicular lymphoma and types of non‐Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcomeAims: Follicular dendritic cells (FDC) are specialized antigen‐presenting cells found exclusively in the germinal centre (GC), which can be detected in B cell non‐Hodgkin lymphomas (NHL) as reactive bystander cells. Recently, gene expression profiling has revealed that FDC networks might be associated with clinical outcome in follicular lymphoma. The aim was to characterize FDC in NHL and to evaluate a possible association with outcome in follicular lymphoma.Methods and results: The extent and immunophenotype of FDC was determined semi‐quantitatively in reactive GC and NHL (follicular lymphoma, angioimmunoblastic T cell lymphoma, mantle cell lymphoma) using fluorescence double staining and digital image analysis. In all NHL tested CD23 and CD35 and CD54 were expressed at relatively low levels on FDC, comparable to FDC found in the dark zone of the GC. However, the extent of FDC networks did not correlate with the clinical outcome of 102 patients with follicular lymphomas treated within a prospectively randomized trial.Conclusions: FDC found in different types of NHL show quantitatively reduced expression of several proteins, suggesting that there are functional differences between FDC in normal GC and NHL. The extent of the FDC networks in follicular lymphoma is not useful as a prognostic marker.
- 14 March 2011
- Published by Wiley in Histopathology
- Vol. 58 (4) , 586-592
Follicular dendritic cells in follicular lymphoma and types of non‐Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcome
Jin M K, Hoster E, Dreyling M, Unterhalt M, Hiddemann W & Klapper W (2011) Histopathology 58, 586–592 Follicular dendritic cells in follicular lymphoma and types of non‐Hodgkin lymphoma show reduced expression of CD23, CD35 and CD54 but no association with clinical outcomeAims: Follicular dendritic cells (FDC) are specialized antigen‐presenting cells found exclusively in the germinal centre (GC), which can be detected in B cell non‐Hodgkin lymphomas (NHL) as reactive bystander cells. Recently, gene expression profiling has revealed that FDC networks might be associated with clinical outcome in follicular lymphoma. The aim was to characterize FDC in NHL and to evaluate a possible association with outcome in follicular lymphoma.Methods and results: The extent and immunophenotype of FDC was determined semi‐quantitatively in reactive GC and NHL (follicular lymphoma, angioimmunoblastic T cell lymphoma, mantle cell lymphoma) using fluorescence double staining and digital image analysis. In all NHL tested CD23 and CD35 and CD54 were expressed at relatively low levels on FDC, comparable to FDC found in the dark zone of the GC. However, the extent of FDC networks did not correlate with the clinical outcome of 102 patients with follicular lymphomas treated within a prospectively randomized trial.Conclusions: FDC found in different types of NHL show quantitatively reduced expression of several proteins, suggesting that there are functional differences between FDC in normal GC and NHL. The extent of the FDC networks in follicular lymphoma is not useful as a prognostic marker.
- 19 October 2007
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 362 (2) , 485-490
Regulation of repp86 stability by human Siah2
- 19 October 2007
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 362 (2) , 485-490
Regulation of repp86 stability by human Siah2
- 25 September 2007
- Published by Wiley in British Journal of Haematology
- Vol. 139 (2) , 217-223
Loss of expression of LyGDI (ARHGDIB), a rho GDP‐dissociation inhibitor, in Hodgkin lymphoma*
Summary: The guanosine triphosphatase (GTPase) inhibitor LyGDI (ARHGDIB, Ly/D4‐GDI, RhoGDIb or RhoGDI 2) is abundantly expressed in haematopoetic cells and possibly plays a role in the onset of apoptosis. Gene expression profiling of Hodgkin cell lines revealed that LyGDI expression was downregulated in these cell lines. The present study evaluated the expression of LyGDI in Hodgkin cells in vivo and studied the function of LyGDI in Hodgkin cell lines in vitro. Our results showed that virtually all Hodgkin and Reed‐Sternberg cells in classical Hodgkin lymphoma lacked LyGDI protein expression. On the other hand, almost all non‐Hodgkin lymphomas, except for anaplastic large cell lymphomas, expressed LyGDI protein. Transfection of the classical Hodgkin cell line L428 with a vector containing full‐length LyGDI‐induced apoptosis in a subset of cells. However, the majority of Hodgkin cells with transgenic expression of LyGDI escaped apoptosis. Our data show that lack of LyGDI expression is a frequent feature of cHL but that it is not of vital importance for the growth and survival of these cells.
- 25 September 2007
- Published by Wiley in British Journal of Haematology
- Vol. 139 (2) , 217-223
Loss of expression of LyGDI (ARHGDIB), a rho GDP‐dissociation inhibitor, in Hodgkin lymphoma*
Summary: The guanosine triphosphatase (GTPase) inhibitor LyGDI (ARHGDIB, Ly/D4‐GDI, RhoGDIb or RhoGDI 2) is abundantly expressed in haematopoetic cells and possibly plays a role in the onset of apoptosis. Gene expression profiling of Hodgkin cell lines revealed that LyGDI expression was downregulated in these cell lines. The present study evaluated the expression of LyGDI in Hodgkin cells in vivo and studied the function of LyGDI in Hodgkin cell lines in vitro. Our results showed that virtually all Hodgkin and Reed‐Sternberg cells in classical Hodgkin lymphoma lacked LyGDI protein expression. On the other hand, almost all non‐Hodgkin lymphomas, except for anaplastic large cell lymphomas, expressed LyGDI protein. Transfection of the classical Hodgkin cell line L428 with a vector containing full‐length LyGDI‐induced apoptosis in a subset of cells. However, the majority of Hodgkin cells with transgenic expression of LyGDI escaped apoptosis. Our data show that lack of LyGDI expression is a frequent feature of cHL but that it is not of vital importance for the growth and survival of these cells.
- 28 February 2006
- Published by Wiley in The Journal of Pathology
- Vol. 209 (2) , 250-257
Immunoglobulin class‐switch recombination occurs in mantle cell lymphomas
Mantle cell lymphoma (MCL) is an IgM‐expressing B cell lymphoma that originates from naive B cells and responds poorly to chemotherapy. We show here that several MCLs harbour isotype‐switched subclones. Similar to the situation in normal B cells, in vitro stimulation of MCL cell lines with CD40 ligand (CD40L) and interleukin‐4 induced expression of activation‐induced cytidine deaminase (AID) and germline transcription at the immunoglobulin heavy chain gene locus. Additionally, the occurrence of switch‐circle transcripts and mature IgG transcripts after stimulation indicated ongoing class‐switch recombination in mantle cell lymphoma cell lines. Furthermore, stimulation of primary MCL cells in vitro induced expression of class‐switched IgG mRNA in the tumour cells. Our data indicate that mantle cell lymphomas have retained the ability to undergo class‐switch recombination if appropriate stimuli, such as the CD40 ligand, are provided. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
- 28 February 2006
- Published by Wiley in The Journal of Pathology
- Vol. 209 (2) , 250-257
Immunoglobulin class‐switch recombination occurs in mantle cell lymphomas
Mantle cell lymphoma (MCL) is an IgM‐expressing B cell lymphoma that originates from naive B cells and responds poorly to chemotherapy. We show here that several MCLs harbour isotype‐switched subclones. Similar to the situation in normal B cells, in vitro stimulation of MCL cell lines with CD40 ligand (CD40L) and interleukin‐4 induced expression of activation‐induced cytidine deaminase (AID) and germline transcription at the immunoglobulin heavy chain gene locus. Additionally, the occurrence of switch‐circle transcripts and mature IgG transcripts after stimulation indicated ongoing class‐switch recombination in mantle cell lymphoma cell lines. Furthermore, stimulation of primary MCL cells in vitro induced expression of class‐switched IgG mRNA in the tumour cells. Our data indicate that mantle cell lymphomas have retained the ability to undergo class‐switch recombination if appropriate stimuli, such as the CD40 ligand, are provided. Copyright © 2006 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.